You might think this only affects older adults with a history of heart problems. Not true. Young women, seemingly healthy athletes, even children have been diagnosed. Which raises the real question: why do some people get it when so many others don’t?
What Exactly Is PAH—and How Is It Different From Regular High Blood Pressure?
First, let’s clear up the confusion. When most people hear “hypertension,” they think of high blood pressure in the systemic circulation—the kind measured with a cuff on your arm. But PAH is entirely different. It’s not about the pressure in your arms or legs. It’s about the pressure in your lungs. Pulmonary arterial hypertension specifically refers to high blood pressure in the pulmonary arteries, the vessels carrying blood from the heart to the lungs to pick up oxygen.
PAH vs. General Pulmonary Hypertension: Why the Distinction Matters
Not all pulmonary hypertension is PAH. In fact, PH (pulmonary hypertension) is a broader category with five groups. PAH is Group 1—and it’s the most insidious. The others stem from left heart disease, lung conditions like COPD, chronic clots, or unclear multifactorial causes. But PAH? It’s defined by constricted, remodeled pulmonary arteries without those other obvious triggers. That means the lungs themselves look structurally normal at first glance. Yet something—some invisible force—is turning their blood vessels into narrow, rigid tubes. That changes everything when it comes to treatment.
The Hidden Mechanism: What Goes Wrong in the Lung Arteries?
The arteries in PAH patients undergo pathological remodeling. Smooth muscle cells proliferate abnormally, the endothelium (inner lining) becomes dysfunctional, and tiny clots form in situ. Vasoconstriction, fibrosis, and inflammation all contribute. Over time, this increases pulmonary vascular resistance. The right ventricle hypertrophies trying to push blood through, then dilates, then fails. It’s a slow-motion train wreck. And the worst part? Symptoms often don’t appear until the damage is already advanced—fatigue, shortness of breath, chest pain, fainting. By then, mean pulmonary arterial pressure has often reached 40 mmHg or higher. Normal is under 20.
The Genetic Puzzle: When PAH Runs in Families
About 5–10% of PAH cases are heritable. That means they’re passed down through families, usually in an autosomal dominant pattern—but with incomplete penetrance. Translation? You can inherit the faulty gene and never develop the disease. The main culprit? Mutations in the BMPR2 gene, which codes for a receptor involved in regulating cell growth in blood vessels. About 70% of heritable PAH cases involve this gene. Yet only 20% of people with the mutation actually develop PAH. So why do some get sick and others don’t? Unknown. Maybe second hits—environmental or immunological—are required. Maybe epigenetics silences or activates the gene differently in each person. Honestly, it is unclear.
There are rarer genetic players too: SMAD9, CAV1, KCNK3. But testing for them isn’t routine. And even if you find a mutation, it doesn’t mean treatment changes—not yet, anyway. But it does mean screening relatives might save lives. I find this underutilized in clinical practice.
Autoimmune Diseases and PAH: The Body Turning on Itself
Connective tissue disorders are major triggers. Systemic sclerosis (scleroderma) is the big one—up to 15% of those patients develop PAH. Lupus, mixed connective tissue disease, and rheumatoid arthritis also increase risk. The immune system, meant to protect, starts attacking endothelial cells in the pulmonary arteries. Inflammation follows. Scarring follows that. Then remodeling. It’s not fully understood why the lungs become a target, but autoantibodies and T-cell infiltration are suspects.
Scleroderma-Associated PAH: A Particularly Vicious Form
This subtype progresses faster and responds less to therapy. Median survival? As low as 3 years without treatment. Early screening with echocardiograms and right heart catheterization is critical. Yet many rheumatologists don’t screen routinely until symptoms arise. That’s a problem. Because by then, the window for effective intervention has often closed. Regular screening in high-risk groups could shift outcomes dramatically. But reimbursement and access get in the way. And that’s exactly where the system fails patients.
HIV and PAH: A Link Few Expect
People living with HIV are up to 10,000 times more likely to develop PAH than the general population. That’s not a typo. Even with effective antiretroviral therapy, the risk remains elevated. The exact mechanism? Possibly chronic immune activation or direct viral effects on endothelial cells. But not everyone with HIV gets PAH. So what’s the differentiator? We’re far from it. Still, every HIV patient with unexplained dyspnea should be evaluated. Too often, it’s chalked up to infection or deconditioning.
Congenital Heart Disease and PAH: A Lifelong Risk
Untreated or partially repaired congenital heart defects—particularly left-to-right shunts like atrial or ventricular septal defects—can lead to Eisenmenger syndrome. Over decades, increased blood flow to the lungs causes irreversible vascular damage. Once the pressure in the pulmonary circuit exceeds systemic pressure, the shunt reverses. Cyanosis sets in. And PAH is now inoperable. Repair before age 2? Low risk. Delay beyond 10? Risk jumps to 50%. Which explains why early intervention is non-negotiable. Some patients born in countries without pediatric cardiac surgery programs arrive in their 30s with advanced disease. To give a sense of scale: that’s like running a marathon every day with half your oxygen supply cut off.
Drugs, Toxins, and PAH: The Triggers We Can Sometimes Control
Some causes are avoidable. Appetite suppressants like fenfluramine (the “fen” in fen-phen) were pulled from the U.S. market in 1997 after studies showed a 7-fold increased risk of PAH. Even decades later, former users still show up in clinics with late-onset disease. Amphetamines and methamphetamine carry similar risks. And then there’s the case of dasatinib, a leukemia drug. It’s effective—but in about 5% of patients, it causes pulmonary vascular toxicity. Stopping the drug doesn’t always reverse it. That’s the scary part. Because sometimes the cure becomes a new disease.
Appetite Suppressants and PAH: A Cautionary Tale
From 1996–1997, over 2 million people took fen-phen. At least 1 in 1,000 developed valvular heart disease or PAH. Some lawsuits led to $13 billion in settlements. But the human cost? Impossible to quantify. These weren’t just obese patients looking to lose weight. Many were young women, already marginalized by body image struggles, now facing life-threatening illness. And yet, similar drugs—like phentermine combinations—are still prescribed today. Are they safer? Possibly. But long-term data is still lacking. We can’t afford to repeat history.
How Toxins Like Benzene or PAH-Inducing Chemicals Contribute
Occupational exposure to toxins—vinyl chloride, benzenes, certain pesticides—has been loosely linked to PAH. The data isn’t robust, but case clusters exist. One study found higher rates among workers in tire manufacturing plants in Ohio during the 1980s. Another pointed to Italian PVC factory workers. Could chronic inflammation from inhaled toxins damage endothelial function over time? It’s plausible. But proving causation? Nearly impossible. That said, minimizing exposure in high-risk industries makes sense. Because why roll the dice?
PAH Without a Cause? The Idiopathic Cases That Baffle Doctors
When no trigger is found, it’s called idiopathic PAH. About 60% of cases fall into this category. These patients aren’t HIV-positive, don’t have scleroderma, didn’t take fen-phen, and test negative for BMPR2. So what’s going on? Maybe undetected autoimmune activity. Maybe viral remnants hiding in lung tissue. Or maybe it’s a perfect storm of micro-insults—air pollution, silent inflammation, minor genetic susceptibilities—that finally tips the scale. One theory gaining traction is the “two-hit hypothesis”: a genetic predisposition plus an environmental insult. But proving it? Not easy.
And here’s the irony: the rarer the disease, the less funding it gets. Research moves slowly. Drug development is expensive. A single year of PAH therapy can cost $150,000. Insurance fights coverage. Patients go bankrupt. Is this the price of progress? We’ve come a long way since the 1990s, when PAH was a death sentence within months. Survival now averages 7 years—with treatment. Some live 20. But access? That’s the real bottleneck.
Frequently Asked Questions
Can Smoking Cause Pulmonary Arterial Hypertension?
Surprisingly, no—not directly. COPD from smoking leads to Group 3 pulmonary hypertension, but not true PAH. That said, smoking worsens nearly every aspect of cardiovascular and lung health. It increases inflammation, reduces oxygen delivery, and accelerates vascular aging. So while it won’t give you PAH per se, it makes surviving it much harder. And if you already have PAH? Quitting isn’t optional. It’s survival.
Is PAH Hereditary Even If No One in My Family Has It?
Possibly. Remember, BMPR2 mutations have incomplete penetrance. Your parent could carry the gene and never get sick. You inherit it, and something else—maybe an infection, maybe a drug—triggers it. Or you develop a new (de novo) mutation. Genetic testing can clarify risk, especially if you’re planning a family. But counseling is crucial. Knowing you carry the mutation can be a heavy burden.
How Long Can You Live With PAH?
It varies wildly. Without treatment, median survival is 2.8 years from diagnosis. With modern therapies—endothelin receptor antagonists, prostacyclins, PDE5 inhibitors—it’s now around 7 years. Some patients exceed 15. Early diagnosis, access to specialists, and adherence to treatment are key. Centers like those at National Jewish Health or Cleveland Clinic see better outcomes. Location matters. Insurance matters more.
The Bottom Line
Why do people get PAH? Because biology is messy. Because genes interact with environment in ways we’re only beginning to map. Because sometimes, a drug meant to help causes harm. Because the immune system can misfire. Because a hole in the heart at birth can unravel decades later. And because in too many cases, we just don’t know. That should be humbling. We’ve made progress—real progress—but we’re far from solving it. My recommendation? Push for earlier screening in high-risk groups. Demand better access to treatments. Fund research into endothelial repair. And stop treating rare diseases like afterthoughts. Because behind every PAH diagnosis is a person who once thought they were fine—until they weren’t.